News

Antibiotic Resistance

  • 09.18.2018  |  Trump Administration releases new US National Biodefense Strategy, stepping up efforts to protect Americans against man-made and natural biological health threats

    WASHINGTON TIMES | The US Government published a new National Biodefense Strategy, calling for improved coordination across the government agencies and better preparedness in the event of a biological threat. The Strategy underscores antimicrobial resistance as a naturally occurring biological threat, saying “Infectious disease threats do not respect borders.” Click here to read the Strategy document

    Full Story

  • 09.14.2018  |  FDA plan focuses on antibiotic development, stewardship: FDA Commissioner Scott Gottlieb

    CIDRAP | The US Food and Drug Administration (FDA) announces a multipronged strategy to address antimicrobial resistance (AMR) that emphasizes new measures to spur development of antibiotics and alternative therapies, promote antibiotic stewardship in animal health, advance antibiotic resistance surveillance, and enhance regulatory science. Gottlieb praises ‘push’ incentives to drive innovation but says ‘pull’ incentives are needed as well.

    Full Story

  • 09.04.2018  |  Challenges of developing AMR diagnostics, particularly for low-resource settings

    LONGITUDE PRIZE BLOG | An interview with Dr. Cassandra Kelly-Cirino, Head of AMR and Outbreaks at the Foundation for Innovative New Diagnostics (FIND), an international non-profit organisation that accelerates the development and delivery of high-quality, affordable diagnostic tests for poverty-related diseases and drug-resistance infections.   

    Full Story

  • 08.08.2018  |  Scourge of superbugs killing Malawi’s babies

    CNN | Malawi is facing an epidemic of infections causing sepsis, particularly among newborns, made worse by ever-increasing drug resistance. Sepsis was responsible for nearly 20% of newborn deaths in 2016. A combination of factors - all related to poverty, insufficient infrastructure and drug resistant bacteria - is at the heart of this tragic situation.

    Full Story

  • 06.26.2018  |  Fighting Infection with Phages

    NIH | Antimicrobial resistance is a serious threat to modern medicine: As MRSA and other bacteria become immune to our most common antibiotics, researchers must develop new ways to fight these pathogens. One of these alternatives actually involves viruses called bacteriophages, which prey on bacteria.  A new video from NIAID explores how phages function, how phage cocktails are assembled, and more.

    Full Story

  • 06.22.2018  |  New center aims to advance bacteriophage therapy

    CIDRAP | Phage research is getting a boost with the creation of a centre at the University of California San Diego that will bring physicians and researchers from the UCSD School of Medicine together to advance research on bacteriophage therapy. Bacteriophage therapy uses viruses that specifically target bacteria to treat patients with multidrug-resistant infections.

    Full Story

  • 05.09.2018  |  Unleashing biotech’s crouching tiger

    NATURE BIOTECHNOLOGY | With a massive expansion in healthcare coverage, biotech's next big boom could occur in India. The country has launched the world's largest publicly funded healthcare scheme. Termed 'Modicare’ which could drive investment into the biotech and pharma sector.

    Full Story

  • 04.15.2018  |  Analysis reveals mechanisms behind pan-resistant pathogen

    CIDRAP | Scientists have identified the resistance strains in the carbapenem-resistant Enterobacteriaceae (CRE) bacteria responsible for the death of a Nevada woman in 2016. She died of septic shock. The CRE bacteria - K pneumoniae - was resistant to 26 different antibiotics and is an example of the type of 'nightmare' bacteria the CDC has detected in hospitals in more than 30 states.

    Full Story

  • 04.03.2018  |  ‘Nightmare bacteria’ widespread in U.S. hospitals

    SCIENTIFIC AMERICAN | The Centers for Disease Control and Prevention detected more than 220 cases last year of a rare breed of “nightmare bacteria” that are virtually untreatable and capable of spreading genes that make them impervious to most antibiotics, according to a report released Tuesday.

    Full Story

  • 03.26.2018  |  Global antibiotic use rises, fueled by economic growth

    CIDRAP | Overall global antibiotic use climbed by 65% from 2000 through 2015. A large new study of antibiotic use in humans shows an alarming rise in consumption around the world, driven predominantly by rising living standards in low- and middle-income countries (LMICs).

    Full Story

  • 03.26.2018  |  The true cost of antibiotic resistance in Britain and around the world

    THE TELEGRAPH | The increasing use of antibiotics both in medicine and farming around the world is constantly causing bacteria to mutate and become resistant to drugs. Although the latest data show the steepest rises in consumption are in developing countries, the problem is a global one as so-called superbugs rapidly spread across the world through international travel, trade and tourism.

    Full Story

  • 03.22.2018  |  Price to pay: Antibiotic-resistant infections cost $2 billion a year

    CIDRAP | US study says cases of drug resistance are on the rise, almost doubling from 2002 to 2014, adding extra costs to health care on top of costing lives.

    Full Story

  • 02.01.2018  |  New BEAM Alliance of biotech companies calls out worldwide stakeholders to support SME-driven innovation and revive the product pipeline fighting antimicrobial resistance

    BEAM ALLIANCE | Position paper: Concerted global action and ‘push and pull’ incentives needed. CARB-X stands out 'at the forefront of innovative funding in AMR and has proven it is possible to take action within a few months to make the difference.

    Full Story

  • 01.15.2018  |  New global approach and greater financial incentives are urgently needed to stimiluate antibiotic innovation

    DRIVE–AB | (Driving reinvestment in research and development for antibiotics and advocating their responsible use) calls for sweeping changes and more money to stimulate antibacterial innovation. DRIVE-AB is a consortium of 16 public-sector partners and seven pharmaceutical companies supported by the European Innovative Medicines Initiative (IMI)

    Full Story